ABCG2 and cancer: The incubation of S1-M1-80 cancer cells with gilteritinib at a concentration of 3 μM (from the cytotoxicity data) for 24, 48 and 72 h and a combination of 3 μM of gilteritinib and 6 μM of VKNG-1 for 72 h remarkably decreased the ABCG2 expression at transcription and translational levels compared to cells incubated with vehicle (Figure 3C,G,H).